Disc Medicine (IRON) Gains from Investment Securities (2020)

Disc Medicine's (IRON) quarterly Gains from Investment Securities came in at $2000.0 in Q4 2020, down 75.0% on a QoQ basis from $8000.0 in Q3 2020.

Disc Medicine (IRON) Gains from Investment Securities (2020) Analysis & Trends

Disc Medicine (IRON) has 1 years of Gains from Investment Securities data on file, last reported at $2000.0 in Q4 2020.

On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $2000.0 in Q4 2020; TTM through Dec 2020 was $8000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $8000.0, changed N/A from the prior year.
Gains from Investment Securities for Q4 2020 stood at $2000.0, down from $8000.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for IRON reached as high as $8000.0 in Q3 2020 and fell as low as -$2000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Disc Medicine	2.89 Bn	2.89 Bn	-

Download Data